Biocompatible Gallium Nanodots against Drug-Resistant Bacterial Pneumonia and Liver Abscess

Area of Science:

• Nanotechnology
• Infectious Diseases
• Materials Science

Background:

• Antibiotic resistance poses a significant global health challenge.
• Conventional antibiotics are increasingly ineffective against multidrug-resistant (MDR) bacteria.
• Novel therapeutic strategies are urgently needed to combat resistant infections.

Purpose of the Study:

• To develop and evaluate gallium-based nanodots (Ga NDs) as a novel therapy for MDR Gram-negative bacterial infections.
• To investigate the efficacy of Ga NDs in suppressing bacterial proliferation and disrupting biofilms.
• To assess the therapeutic potential of Ga NDs in preclinical infection models.

Main Methods:

• Synthesis and characterization of gallium-based nanodots (Ga NDs).
• In vitro testing against MDR bacterial strains (P. aeruginosa, ESBL E. coli) and their biofilms.
• In vivo evaluation in mouse models of pneumonia and acute liver abscess.

Main Results:

• Ga NDs significantly inhibited the growth of MDR P. aeruginosa and ESBL E. coli compared to penicillin and levofloxacin.
• Ga NDs effectively disrupted bacterial biofilms.
• In vivo studies showed substantial bacterial growth inhibition, reduced organ inflammation, and improved survival rates.
• Ga NDs exhibited excellent biocompatibility and biosafety.

Conclusions:

• Gallium-based nanodots are a promising therapeutic candidate for treating multidrug-resistant bacterial infections.
• Ga NDs offer a novel mechanism of action by targeting bacterial iron acquisition.
• Further development of these nanotherapeutics could provide a vital alternative to conventional antibiotics.